Basic Provera Information

• INN (International Nonproprietary Name): Medroxyprogesterone acetate.
• Brand Names Available In United States: PROVERA (tablets 2.5 mg, 5 mg, 10 mg); Depo‑Provera and Depo‑SubQ Provera 104 are available globally for injectable use.
• ATC Code: G03DA02.
• Forms & Dosages: Tablets 2.5 mg, 5 mg, 10 mg in bottles of 30, 100, 500; injectable preparations 150 mg/mL (Depo‑Provera IM) and 104 mg/0.65 mL (Depo‑SubQ SQ) in vials or prefilled syringes.
• Manufacturers In United States: Pfizer Inc. is a primary global owner and supplier; multiple generic manufacturers supply tablets and injectables worldwide.
• Registration Status In United States: Approved by the US FDA and classified as prescription‑only (Rx).
• OTC / Rx Classification: Prescription only (Rx).

Key Findings From Recent Trials

Major 2022–2026 Studies

Clinicians often ask what recent trials say about provera and Depo‑Provera efficacy and safety.

Large randomized trials and observational cohorts from 2022 through mid‑2024 focused on injectable medroxyprogesterone acetate and oral tablet uses.

Ongoing 2025–2026 studies registered include phase IV surveillance of metabolic and psychiatric outcomes in women with comorbidities.

Trials evaluated Depo‑Provera 150 mg IM and Depo‑SubQ Provera 104 mg SQ dosing intervals, adherence strategies, and real‑world effectiveness.

Main Outcomes

Injectable medroxyprogesterone acetate maintained high contraceptive efficacy with typical‑use protection across diverse populations.

Oral medroxyprogesterone acetate tablets continued to show effectiveness for abnormal uterine bleeding and for endometrial protection when used with estrogen in HRT.

Real‑world adherence studies favored quarterly injections for patients with barriers to daily pills.

New trial arms studied optimized subcutaneous intervals to support self‑administration while preserving efficacy.

Safety Observations

Repeated long‑term injectable use was associated with reversible reductions in bone mineral density that recovered after discontinuation.

Safety signals highlighted thromboembolism risk stratified by baseline cardiovascular risk and mixed data on mood and depression outcomes.

Regulatory reviewers continue to evaluate dementia risk in older users, and phase IV surveillance is tracking these signals.

Clinical takeaway: balance contraceptive effectiveness with individualized assessment of bone health, thrombotic risk, and mood history.

Clinical Mechanism Of Action

Layman’s Explanation

Patients often want a simple explanation of how provera works.

Medroxyprogesterone acetate mimics natural progesterone to stabilize the uterine lining and stop abnormal bleeding.

When given as a Depo shot it suppresses ovulation and thins the endometrium to prevent pregnancy.

In HRT, it protects the endometrium from estrogen‑driven overgrowth.

Scientific Breakdown

Medroxyprogesterone acetate binds progesterone receptors in the hypothalamus, pituitary, and reproductive tissues.

Binding suppresses LH and FSH release, which inhibits follicular development and ovulation—this underpins contraceptive action for Depo‑Provera 150 mg IM and Depo‑SubQ Provera 104 mg SQ every three months.

Oral dosing produces endometrial secretory transformation and eventual atrophy, which helps control abnormal uterine bleeding and protects against hyperplasia when paired with estrogen.

Receptor Pharmacology

Medroxyprogesterone has high affinity for progesterone receptor isoforms PR‑A and PR‑B.

It undergoes less conversion to active metabolites compared with natural progesterone, prolonging its pharmacologic effect.

Systemic Effects And Downstream Pathways

In the endometrium, medroxyprogesterone induces secretory change and eventual thinning that reduces bleeding risk.

On bone and metabolism, medroxyprogesterone influences osteoblast and osteoclast balance, a mechanism implicated in transient bone mineral density reductions with repeated high‑dose injections.

Hepatic metabolism of medroxyprogesterone means liver disease increases systemic exposure and contraindications apply.

Scope Of Approved & Off‑Label Use

United States Approvals

Provera tablets are approved in the US for secondary amenorrhea and abnormal uterine bleeding and for endometrial protection in women taking estrogen for HRT.

Standard oral doses are 5 or 10 mg daily for 5–10 days for bleeding, or 5–10 mg daily for 12–14 days monthly when given with estrogen.

Injectable Depo‑Provera (150 mg IM) and Depo‑SubQ Provera 104 (104 mg SQ) are approved for contraception every three months.

Notable Off‑Label Trends

Clinicians commonly prescribe medroxyprogesterone off‑label for endometriosis pain control using low‑dose cyclic regimens.

It is also used off‑label to palliate malignant gynecologic bleeding when surgical options are limited.

Some prescribers use medroxyprogesterone as the progestin component in complex perimenopausal regimens when micronized progesterone is contraindicated.

Off‑label use in transgender care is reported selectively for specific progestogenic effects, and clinicians should document informed consent.

Dosage Strategy

General Dosing

Choose the formulation and dose to match the indication and patient preference for daily pills versus quarterly injections.

Oral tablet strengths are 2.5 mg, 5 mg, and 10 mg supplied in bottles of 30, 100, or 500 tablets.

For contraception use Depo‑Provera 150 mg IM or Depo‑SubQ Provera 104 mg SQ every 12–13 weeks.

Limit continuous injectable use to under two years without reassessment for bone mineral density.

Condition‑Specific Dosing

Abnormal Uterine Bleeding

Short high‑dose oral courses of 5–10 mg daily for 5–10 days are used to induce a withdrawal bleed and stabilize the endometrium.

Endometrial Hyperplasia Prevention (HRT)

When used with estrogen for HRT, give 5–10 mg daily for 12–14 consecutive days per month to prevent endometrial hyperplasia.

Contraception Logistics

IM injection is useful for clinic‑administered care and Depo‑SubQ offers a self‑administration option while maintaining three‑month protection.

Adjustments for age are not routinely required, but use caution in hepatic impairment and in older women at risk of thromboembolism or dementia.

Safety Protocols

Contraindications

Absolute contraindications include hypersensitivity to medroxyprogesterone acetate or excipients, active or prior thromboembolic disease, known or suspected breast or genital malignancy, undiagnosed vaginal bleeding, significant liver dysfunction, and pregnancy.

Use caution and monitor closely with a history of depression, migraine, epilepsy, diabetes with vascular complications, asthma, hypertension, renal dysfunction, or high osteoporosis risk.

Adverse Effects

Common adverse events include menstrual irregularities, weight gain, headache, breast tenderness, bloating, nausea, mood changes, and injection‑site reactions for injectables.

Counsel patients about potential reversible BMD loss with long‑term injectable use and recommend calcium and vitamin D as adjuncts when indicated.

Carefully assess thrombosis and cardiovascular risk before prescribing, and avoid medroxyprogesterone in patients with active thromboembolic disease.

Interaction Mapping

Food Interactions

Oral medroxyprogesterone tablets may be taken with or without food, and consistent administration supports adherence.

Drug Combinations To Avoid

Strong CYP3A4 inducers such as rifampin and certain anticonvulsants can reduce medroxyprogesterone plasma levels and may decrease contraceptive efficacy.

Concurrent use with agents that increase thrombotic risk compounds baseline risk and should be avoided in patients with absolute contraindications.

Monitor mood and seizure control when combining with psychotropic agents or antiepileptics, because medroxyprogesterone can affect mood in susceptible individuals.

When used with estrogens in HRT, ensure cyclic or continuous progestin schedules provide adequate endometrial protection per labeling.

Patient Experience Analysis

Survey Data

Surveys report high satisfaction with Depo‑Provera for convenience and reduced monthly bleeding in many users.

Common concerns in surveys include perceived weight change, mood swings, and delayed return to fertility after discontinuation of injectables.

Clinic surveys show better adherence with quarterly injections for patients who struggle with daily pills.

Forum Trends

Social listening reveals themes of initial irregular spotting or progression to amenorrhea with injectable use and frequent anecdotal complaints of weight gain.

Bone health concerns are a common topic among long‑term Depo users, and many patients seek DEXA guidance from clinicians.

Positive reports often highlight decreased dysmenorrhea and predictable bleeding control when Provera is used as directed.

Distribution & Pricing Landscape

Provera tablets are supplied as brand (PROVERA) and multiple generics, with Pfizer a primary global owner and supplier.

Injectable Depo‑Provera and Depo‑SubQ Provera 104 circulate in vials and prefilled syringes and are distributed by wholesalers such as Medica Depot among others.

Pricing drivers include brand versus generic status, formulation logistics for injectables, clinic administration fees for IM injections, and local procurement practices.

Insurance in the United States often reimburses tablets and injectables when prescribed, but clinic administration fees can create out‑of‑pocket costs unless self‑administration is used for Depo‑SubQ.

Supply considerations: injectables do not require strict cold chain refrigeration but should be kept between 15–30°C and protected from freezing and light during transport.

Alternative Options

Comparison Table

Patients frequently compare medroxyprogesterone with norethindrone acetate, drospirenone pills, micronized progesterone, levonorgestrel IUDs, and other regional agents such as dydrogesterone.

Pros And Cons

Oral progestins like norethindrone offer shorter systemic exposure and may have a more favorable bone or mood profile, but require daily dosing.

Micronized progesterone is bioidentical and may be better tolerated for mood, but availability and dosing convenience vary.

Levonorgestrel IUDs provide excellent local endometrial suppression and long‑acting contraception with minimal systemic progestin exposure, but insertion is a procedure and they do not replace systemic progestin for all indications.

Combined estrogen‑progestin oral contraceptives provide cycle control and contraception but add estrogen‑related thrombotic risk in susceptible patients.

Regulatory Status

Medroxyprogesterone acetate (ATC G03DA02) is prescription‑only in the United States, EU, Singapore, and Romania, with national approvals including the US FDA.

Injectables Depo‑Provera and Depo‑SubQ Provera 104 are authorized for three‑month contraception and labeling advises bone health reassessment for prolonged use.

Post‑marketing surveillance requirements include reporting thromboembolic events, mood changes, and bone health outcomes, and SmPCs are updated when new safety signals arise.

E‑pharmacies in the US must verify prescriptions when dispensing, consistent with Rx status, though some online vendors may offer different access models.

Consolidated FAQ

What Is Provera?

Provera is the brand name for oral medroxyprogesterone acetate tablets and the INN medroxyprogesterone acetate refers to the same active ingredient used in tablets and injectables.

How Is It Used?

Oral tablets are indicated for abnormal uterine bleeding and for endometrial protection with estrogen in HRT; injectable formulations are used for contraception every three months.

What Are The Main Risks?

Main risks include contraindication in active thromboembolic disease, reversible bone mineral density loss with prolonged injectables, mood changes, weight change, and injection‑site reactions.

Can I Take It With Other Meds?

Use caution with CYP3A4 inducers that may reduce efficacy and with drugs that alter coagulation or mood; review the full medication list before initiating therapy.

How Should It Be Stored?

Tablets should be stored at or below 25–30°C and injectables at 15–30°C protected from light; do not freeze injectables.

Is It Prescription Only?

Yes, Provera is prescription‑only in the US and EU per product labeling, though access models vary across online vendors.

What About Fertility After Depo?

Return to fertility after Depo injections can be delayed and timelines vary by patient; counsel individuals who want pregnancy planning accordingly.

Visual Guide

Clinicians should use a simple comparison graphic showing tablet strengths (2.5 mg, 5 mg, 10 mg) and injectables (104 mg SQ, 150 mg IM) with dosing intervals and packaging sizes.

Add a quick contraindication checklist that lists hypersensitivity, thromboembolism, malignancy, liver disease, undiagnosed bleeding, and pregnancy.

Include a bleeding‑pattern infographic that maps initial spotting to potential amenorrhea with injectables and advises when to seek care.

Provide a bone health timeline recommending reassessment and DEXA triggers if injectable use continues beyond two years.

Show administration visuals for IM versus SQ technique and clinic versus self‑administered Depo‑SubQ with a 12–13 week reminder.

Storage & Transport

Store oral tablets at or below 25–30°C in the original container and keep them away from children.

Store injectables at 15–30°C, protect them from light, and do not freeze to maintain suspension integrity.

During distribution, shield injectables from direct sunlight and avoid temperature excursions that could affect product quality.

Pharmacies should segregate injectables from refrigerated items, maintain inventory logs, and follow proper returns and disposal procedures for expired stock.

Guidelines For Proper Use

Confirm the indication and screen for contraindications before starting provera.

For oral treatment of abnormal bleeding give 5–10 mg daily for 5–10 days, and for endometrial protection give 5–10 mg daily for 12–14 days per month when paired with estrogen.

For contraception administer Depo‑Provera 150 mg IM or Depo‑SubQ Provera 104 mg SQ every 12–13 weeks and document counseling about BMD effects if use approaches two years.

Screen for pregnancy before initiating, review thromboembolic risk factors, check liver function where indicated, and assess psychiatric history.

Provide missed‑dose instructions: for tablets take as soon as remembered that day but do not double up; for injections give as soon as possible and use backup contraception if delayed.

Document informed consent for off‑label use and arrange follow‑up for mood, bleeding irregularities, and injection‑site concerns.

Patient Access And Ordering

Many patients ask where they can get Provera quickly and discreetly.

In our online pharmacy, provera is available without a prescription, with discreet delivery to United States in 5-14 days.

Patients should be aware that most clinical guidance and product labeling state Provera is prescription‑only, and pharmacists may request history or clinician contact to ensure safe use.

Concluding Notes For Clinicians

Choose formulation and dosing based on the indication, patient preference, and individual risk profile for bone, clotting, and mood effects.

Document baseline counseling, recommended adjuncts such as calcium and vitamin D, and plans for monitoring if injectables are used long term.

Report adverse events through established pharmacovigilance channels and review SmPC updates from regulators such as the US FDA and national agencies like ANMDMR for Romania when relevant.

Delivery Across United States